Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noglux (Bioksan)
- Development stage
- Preclinical
- Lead developer
- Bioksan
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Noglux is a multi-ingredient nutraceutical formulation developed by Bioksan Naturalmente Juntos, specifically designed for glycemic control and the management of prediabetes, metabolic syndrome, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). The formulation contains a synergistic blend of active ingredients: white mulberry (*Morus alba*) leaf extract (standardized as Reducose, containing the alpha-glucosidase inhibitor 1-deoxynojirimycin), fenugreek (*Trigonella foenum-graecum*) extract (an AMPK activator), inulin (a prebiotic soluble fiber), *Lactiplantibacillus plantarum* A7 (a probiotic), niacin (vitamin B3), chromium, and zinc. Noglux acts by slowing carbohydrate digestion and sugar absorption, improving insulin sensitivity, reducing systemic inflammation (C-reactive protein), and mitigating liver fibrosis risk (as measured by FIB-4 scores).
- Brand names
- Noglux
- Other names
- Noguxwhite mulberry + fenugreek + inulin + niacin + chromium + zincwhite mulberry leaf extract + fenugreek + inulin + niacin + chromium + zinc
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)Sucrase-IsomaltaseHCAR2 (Hydroxycarboxylic acid receptor 2)INSR (Insulin receptor)
Beyond the preview
Go deeper on Noglux (Bioksan).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noglux (Bioksan).